Found and Mounjaro: How the Tirzepatide Question Works

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Pairing the Mounjaro brand name with a telehealth program raises a specific question about the compound behind it: tirzepatide. This independent review answers it. Browse the Peptides & GLP-1 education library.

This editorial analysis comes from PlexusDx. We have no commercial relationship with Found, with the makers of Mounjaro, or with any parent company, and no affiliate links are involved.

Full head-to-head: PlexusDx vs Found →

Below we clarify what Mounjaro is, how a subscription telehealth service like Found may or may not fit into that picture, and what the tirzepatide molecule does. Balanced framing, not a buying recommendation. As of April 2026.

Mounjaro and the tirzepatide behind the name

Mounjaro is a brand name for tirzepatide, an FDA-approved prescription product. When people search Found alongside Mounjaro, they are usually asking whether the program can connect them to that compound or to a compounded equivalent, which is a different question from the brand itself.

How Found may handle branded versus compounded

Telehealth programs in this model route prescriptions in one of two directions: to a retail pharmacy for an FDA-approved brand product, or to a 503A compounding pharmacy for compounded tirzepatide. Which pathway applies depends on eligibility, availability, and program structure. The current specifics live on Found's own website, and they change.

How the program flow works

Eligibility review

A licensed clinician evaluates intake information before any tirzepatide-class prescription is considered.

Pharmacy routing

An eligible prescription is sent to either a retail or a 503A compounding pharmacy for fulfillment.

Titration support

Follow-up visits help manage dose adjustments and gastrointestinal side effects over time.

What tirzepatide's dual-agonist mechanism does

Tirzepatide is a GIP/GLP-1 dual agonist, meaning it engages two incretin pathways rather than the single GLP-1 receptor that agonists like semaglutide target. Engaging both the GIP and GLP-1 systems is what distinguishes the dual-agonist class from single-receptor agonists, and it is the reason the compound is studied as its own category. The SURMOUNT program (tirzepatide for weight management, The New England Journal of Medicine, 2022) and SURMOUNT-OSA (obstructive sleep apnea, NEJM 2024) studied the compound across different endpoints and populations. Those trials examined the molecule under defined conditions, so their results describe tirzepatide itself, not any single brand or telehealth program, and individual outcomes vary.

The genetic terrain tirzepatide acts on

Whether tirzepatide arrives as branded Mounjaro or a compounded preparation, it acts on a metabolic baseline set partly by your genes. Variants in TCF7L2, a transcription factor tied to glucose homeostasis and incretin signaling, and GLP1R, one of the receptors involved in incretin response, describe that terrain. These are pathway-level markers, not predictions of how you will respond. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including TCF7L2 variants that map your baseline glucose-regulation and receptor biology before any dual-agonist protocol begins.

PlexusDx and the tirzepatide pathway

PlexusDx offers tirzepatide directly through its Weight Management Protocols, including Tirzepatide Injection and Tirzepatide Oral, paired with the genetic context that telehealth-only programs typically leave out. The differentiator is putting the pathway insight next to the protocol rather than dispensing the compound on its own, so the decision starts from your baseline biology instead of a brand name.

No affiliation: PlexusDx is independent of Found and of the makers of Mounjaro, and holds no commercial relationship with the programs discussed here.

More from the PlexusDx library: Mounjaro Cost, Mounjaro For Weight Loss, Mounjaro Price, and Mounjaro vs Zepbound.

Disclaimer: This article is educational. PlexusDx is not affiliated with Found or with the makers of Mounjaro and compares approaches across the GLP-1 telehealth space, including its own Weight Management Protocols. The Precision Peptide Genetic Test examines how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before starting any peptide protocol.

Frequently Asked Questions

Is Mounjaro the same as tirzepatide?

Mounjaro is a brand name for the compound tirzepatide, an FDA-approved GIP/GLP-1 dual agonist. Searches that combine a telehealth program with Mounjaro are usually asking about access to that compound or a compounded equivalent, which depends on the program's eligibility rules and pharmacy routing.

Can a telehealth program prescribe branded Mounjaro?

Programs in this model can route prescriptions to a retail pharmacy for an FDA-approved brand product or to a 503A pharmacy for a compounded preparation. Which applies depends on eligibility and availability. Confirm current specifics on the brand's own site rather than assuming a fixed pathway.

How is tirzepatide different from a GLP-1 receptor agonist?

Tirzepatide engages two incretin pathways as a GIP/GLP-1 dual agonist, whereas agonists like semaglutide target the single GLP-1 receptor. The SURMOUNT trials studied tirzepatide across weight-management and sleep-apnea endpoints, describing the molecule itself; individual outcomes still vary.

What genes shape the tirzepatide pathway?

Pathway-level variants such as TCF7L2 describe the glucose-regulation and receptor biology tirzepatide acts on. They do not predict your response. The Precision Peptide Genetic Test reads these markers to add upstream context before any protocol, informing your conversation with a provider.

Keep reading in the PlexusDx Education Hub. Browse Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.